Celsion Corporation (NASDAQ: CLSN) is 122.22% higher on its value in year-to-date trading and has touched a low of $0.43 and a high of $6.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CLSN stock was last observed hovering at around $1.72 in the last trading session, with the day’s loss setting it -0.14% off its average median price target of $4.00 for the next 12 months. It is also 60.5% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are 60.5% higher than the price target low of $4.00 for the same period.
Currently trading at $1.58, the stock is -21.59% and -15.36% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.37 million and changing -8.14% at the moment leaves the stock 13.06% off its SMA200. CLSN registered 85.88% gain for a year compared to 6-month gain of 116.14%. The firm has a 50-day simple moving average (SMA 50) of $2.0953 and a 200-day simple moving average (SMA200) of $1.1014.
The stock witnessed a -23.30% loss in the last 1 month and extending the period to 3 months gives it a 114.94%, and is -22.93% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.67% over the week and 12.77% over the month.
Celsion Corporation (CLSN) has around 27 employees, a market worth around $121.25M and $0.50M in sales. Distance from 52-week low is 267.02% and -75.69% from its 52-week high. The company has generated returns on investments over the last 12 months (-80.60%).
Celsion Corporation (CLSN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Celsion Corporation (CLSN) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Celsion Corporation is expected to release its quarterly report on 05/19/2021 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 12.90% this year.
Celsion Corporation (CLSN) Top Institutional Holders
51 institutions hold shares in Celsion Corporation (CLSN), with 936.14k shares held by insiders accounting for 1.25% while institutional investors hold 18.22% of the company’s shares. The shares outstanding are 75.01M, and float is at 63.23M with Short Float at 5.68%. Institutions hold 17.99% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 1.27 million shares valued at $0.9 million. The investor’s holdings represent 1.69% of the CLSN Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 0.71 million shares valued at $0.5 million to account for 0.95% of the shares outstanding. The other top investors are Gsa Capital Partners Llp which holds 0.27 million shares representing 0.36% and valued at over $0.19 million, while Geode Capital Management, LLC holds 0.33% of the shares totaling 0.24 million with a market value of $0.17 million.
Celsion Corporation (CLSN) Insider Activity
A total of 0 insider transactions have happened at Celsion Corporation (CLSN) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Celsion Corporation (CLSN): Who are the competitors?
The company’s main competitors (and peers) include ZIOPHARM Oncology Inc. (ZIOP) that is trading 36.69% up over the past 12 months and Dare Bioscience Inc. (DARE) that is 79.35% higher over the same period. Exelixis Inc. (EXEL) is 28.15% up on the 1-year trading charts. Short interest in the company’s stock has risen 42.06% from the last report on Feb 11, 2021 to stand at a total of 2.08 million short shares sold with a short interest ratio of 0.14.